期刊
IMMUNOTHERAPY
卷 12, 期 5, 页码 287-292出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2020-0014
关键词
hepatocellular carcinoma; immune checkpoint inhibitor; ipilimumab; liver transplant
类别
Organ transplant recipients are not routinely included in clinical trials, and as a result there is a paucity of data to guide clinicians in the treatment of malignancies in this unique patient population. This is a case report and focused review of the treatment of hepatocellular carcinoma in patients with orthotopic liver transplants. We describe a single patient's treatment over a period of 4 years from the time of diagnosis to submission of this case report. We submit evidence that the anti-CTLA-4 antibody ipilimumab can produce a durable response, with a tolerable adverse event profile and without associated allograft rejection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据